These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
223 related articles for article (PubMed ID: 16633092)
1. Metabolic syndrome, new onset diabetes, and new end points in cardiovascular trials. Haffner SM; Ruilope L; Dahlöf B; Abadie E; Kupfer S; Zannad F J Cardiovasc Pharmacol; 2006 Mar; 47(3):469-75. PubMed ID: 16633092 [TBL] [Abstract][Full Text] [Related]
2. Metabolic syndrome: treatment of hypertensive patients. Israili ZH; Lyoussi B; Hernández-Hernández R; Velasco M Am J Ther; 2007; 14(4):386-402. PubMed ID: 17667215 [TBL] [Abstract][Full Text] [Related]
3. [Antihypertensive agents and the risk of new onset diabetes mellitus]. Kuzmanić D; Laganović M; Dika Z; Kos J; Pećin I Lijec Vjesn; 2006; 128(11-12):336-41. PubMed ID: 17212194 [TBL] [Abstract][Full Text] [Related]
4. Effect of metabolic syndrome or type II diabetes mellitus on the occurrence of recurrent vascular events in hypertensive patients. Vlek AL; van der Graaf Y; Spiering W; Visseren FL; J Hum Hypertens; 2008 May; 22(5):358-65. PubMed ID: 18273039 [TBL] [Abstract][Full Text] [Related]
5. Long-term risk of diabetes, hypertension and left ventricular hypertrophy associated with the metabolic syndrome in a general population. Mancia G; Bombelli M; Facchetti R; Madotto F; Corrao G; Trevano FQ; Giannattasio C; Grassi G; Sega R J Hypertens; 2008 Aug; 26(8):1602-11. PubMed ID: 18622239 [TBL] [Abstract][Full Text] [Related]
6. Risk constellations in patients with the metabolic syndrome: epidemiology, diagnosis, and treatment patterns. Haffner SM Am J Med; 2006 May; 119(5 Suppl 1):S3-9. PubMed ID: 16563945 [TBL] [Abstract][Full Text] [Related]
7. The metabolic syndrome in hypertension: European society of hypertension position statement. Redon J; Cifkova R; Laurent S; Nilsson P; Narkiewicz K; Erdine S; Mancia G; J Hypertens; 2008 Oct; 26(10):1891-900. PubMed ID: 18806611 [TBL] [Abstract][Full Text] [Related]
13. Protective role of pravastatin in the pathogenesis of the metabolic syndrome. Yamagishi S; Matsui T; Sato T; Takeuchi M Med Hypotheses; 2006; 66(3):609-11. PubMed ID: 16171951 [TBL] [Abstract][Full Text] [Related]
14. Fenofibrate for cardiovascular disease prevention in metabolic syndrome and type 2 diabetes mellitus. Steiner G Am J Cardiol; 2008 Dec; 102(12A):28L-33L. PubMed ID: 19084087 [TBL] [Abstract][Full Text] [Related]
15. PPARs as targets for the modulation of cardiovascular risk factors associated with the metabolic syndrome. Fernandez AZ Curr Opin Investig Drugs; 2004 Sep; 5(9):936-40. PubMed ID: 15503647 [TBL] [Abstract][Full Text] [Related]
16. Importance of diagnosing and treating the metabolic syndrome in reducing cardiovascular risk. Smith SR Obesity (Silver Spring); 2006 Jun; 14 Suppl 3():128S-134S. PubMed ID: 16931494 [TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of metabolic syndrome by different definitions in a population with high prevalence of obesity and diabetes: the Strong Heart Study. de Simone G; Devereux RB; Chinali M; Best LG; Lee ET; Galloway JM; Resnick HE; Diabetes Care; 2007 Jul; 30(7):1851-6. PubMed ID: 17440172 [TBL] [Abstract][Full Text] [Related]
18. The metabolic syndrome: evolving evidence that thiazolidinediones provide rational therapy. Wyne KL Diabetes Obes Metab; 2006 Jul; 8(4):365-80. PubMed ID: 16776743 [TBL] [Abstract][Full Text] [Related]
19. Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy. Grundy SM Nat Rev Drug Discov; 2006 Apr; 5(4):295-309. PubMed ID: 16582875 [TBL] [Abstract][Full Text] [Related]
20. New drugs and clinical trials in diabetes and hypertension. Nilsson P Exp Clin Endocrinol Diabetes; 1997; 105 Suppl 2():64-9. PubMed ID: 9288549 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]